metys pharmaceuticals ag logo

Metys Pharmaceuticals AG

Metys Pharmaceuticals is developing MP-101 to prevent and treat chemotherapy-induced peripheral neuropathy, an uncomfortable and troubling side effect of several important cancer treatments.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://metys-pharma.ch
Founded2013
Disease Focus
Development Stage
STOCK CODENon Listed
Address
Leimenstrasse 57 4051
Basel
Switzerland
Email
Contact Number
+41 61 568 40 70

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/metys-pharmaceuticals” connections=”true” suffix=””]